The bankrupt drugmaker and OxyContin manufacturer will be dissolved and its assets transferred to a new company.

The court examined the amendments introduced by the Finance Act, 2017, which expanded the reassessment period from six years to ten years, subject to certain conditions. The Revenue contended that the ...